Keep Up With McLean!
Receive the latest news in your inbox each month.
Tremendous advances in science and technology have enabled greater understanding of the brain, yet mental health care remains inaccessible and inadequate for much of the world’s population.
McLean Hospital’s Institute for Technology in Psychiatry (ITP) brings together thought leaders in health care, data science, technology, industry, patient advocacy, academic research, and more for this two-day summit to build on the promise of technology in the diagnosis and delivery of mental health care.
This event is targeted at an inclusive group of academics, data scientists, clinicians, technology developers, entrepreneurs, policymakers, investors, patient advocates, and health professionals who are interested in shaping the future of mental health care.
The ITP partners with like-minded organizations looking to integrate technology into the field of psychiatry to improve research and care. If you are interested in affiliating your brand with the Technology in Psychiatry Summit, please contact the ITP.
The 2019 Technology in Psychiatry Summit will be held on October 28-29, 2019 at Harvard Medical School’s Joseph B. Martin Conference Center in Boston.
Deep discounts are available to students and academic trainees. Contact the ITP for details.
As research around digital psychiatry rapidly expands, it has become evident that there remains a vast potential for the application of technology across clinical populations. The 2019 summit will focus on understanding how the application of technology varies among children, adolescents, young adults, and older adults. The conference will further explore how technology can enhance care in major neuropsychiatric disorders such as autism and dementia. For the first time, the meeting will also invite panel proposals from researchers around the world. With this in mind, the theme of the summit will be “The Future of Mental Health Across the Life Span.”
With keynote addresses, panel discussions, and a poster session, attendees will examine the evolving state of global mental health efforts, cutting-edge trends in neurosciences, and new technologies and analytical tools that are cross-cutting traditionally separate disciplines to help address some of the world’s most challenging mental health problems.
Professionals from across disciplines are invited to submit proposals for oral and poster presentations at the 2019 Technology in Psychiatry Summit. Proposals are due by Friday, June 14, 2019 11:59pm EST, and selected presenters will be notified by July 12, 2019.
Molly Coye, MD, MPH, is executive in residence at AVIA, the leading network for health systems seeking to innovate and transform through the deployment of digital solutions. At AVIA, she is the executive sponsor for the Medicaid Transformation Project, which brings together more than 20 health systems to focus on care models and scalable solutions addressing the needs of vulnerable populations. She is an elected member of the National Academy of Medicine), a member of the Board of Directors of Aetna, Inc., and founded and led HealthTech, which became the premier forecasting organization for emerging technologies in health care. She has previously served as commissioner of Health for the State of New Jersey and director of the California State Department of Health Services.
Joshua A. Gordon, MD, PhD, is the director of the National Institute of Mental Health, the lead federal agency for research on mental disorders. He oversees an extensive research portfolio of basic and clinical research that seeks to transform the understanding and treatment of mental illnesses, paving the way for prevention, recovery, and cure. His own research focuses on the analysis of neural activity in mice carrying mutations of relevance to psychiatric disease and has direct relevance to schizophrenia, anxiety disorders, and depression. Previously, he served on the faculty of Columbia University.
Saul Levin, MD, MPA, FRCP-E, is the chief executive officer and medical director of the American Psychiatric Association (APA). He previously was the head of the Department of Health of Washington, DC, vice president for Science, Medicine & Public Health for the American Medical Association, and the president & CEO of MESAB (Medical Education for South Africans Blacks), an educational trust started during apartheid to provide medical and professional scholarships for Blacks to become doctors, dentists, and health care professionals. His career has focused on integrating primary care, mental health, and substance use disorders, for which he received the Royal College of Physicians fellowship. He is a full professor at Department of Psychiatry, George Washington University.
Our initiative to build a more accessible future is made possible by the support of gracious companies with like-minded goals. Become a sponsor of the 2019 Technology in Psychiatry Summit to help us further our mission to close the gaps between study and practice in mental health care.
For more information on sponsoring the 2019 Technology in Psychiatry Summit, please contact Sue DeMarco at 617.855.3451.
We wish to thank the 2019 sponsors of the Technology in Psychiatry Summit.
We are also grateful for the support of our past sponsors.
The 2018 Technology in Psychiatry Summit was held on November 1-2, 2018. The theme was “Closing Gaps in Translation,” both in the sense of using technology and pervasive sensing approaches to advance the detailed cross-species study of behavior in order to help bridge the human-nonhuman translational gap, as well as applying these approaches to improve mental health in under-resourced areas both globally and in the US (i.e., developing robust cross-cultural models of mental illness and culturally-tailored therapeutics).
Michelle A. Williams, SM, ScD, Harvard T.H. Chan School of Public Health
Dr. Williams is the dean of the Faculty at the Harvard T.H. Chan School of Public Health. She is an internationally renowned epidemiologist and public health scientist, an award-winning educator, and a widely recognized academic leader. Prior to becoming dean in 2016, she was professor and chair of the Department of Epidemiology at the Harvard T.H. Chan School of Public Health and program leader of the Population Health and Health Disparities Research Programs at Harvard’s Clinical and Translational Sciences Center.
Alex “Sandy” Pentland, PhD, MIT Connection Science and Human Dynamics Labs
Dr. Pentland is the director of the MIT Connection Science and Human Dynamics labs and previously helped create and direct the MIT Media Lab and the Media Lab Asia in India. He is one of the most-cited scientists in the world, and Forbes recently declared him one of the “seven most powerful data scientists in the world.” He has received numerous awards and prizes such as the McKinsey Award from Harvard Business Review, the 40th Anniversary of the Internet from DARPA, and the Brandeis Award for work in privacy.
Bruce Cuthbert, PhD, NIMH Research Domain Criteria
Dr. Cuthbert is the director of the NIMH Research Domain Criteria (RDoC) project to develop neuroscience-based criteria for studying mental disorders. He previously served as the director of the Division of Adult Translational Research and Treatment Development and as the chief of the Adult Psychopathology Research Branch at NIMH. He is known for his research on the psychophysiology of emotion and translational research on the psychopathology of anxiety disorders. He was elected president of the Society for Psychophysiological Research in 2004, and is a fellow of the Association for Psychological Science.
Opening remarks were delivered by Scott L. Rauch, MD, president and psychiatrist in chief, McLean Hospital, and Justin T. Baker, MD, PhD, scientific director of the McLean Institute for Technology in Psychiatry. Closing remarks were offered by Kerry J. Ressler, MD, PhD, chief scientific officer, McLean Hospital.
Technology is already narrowing gaps in our ability to translate mental health care strategies across global and local contexts, sometimes taking successes from the developing world and applying them in under-resourced areas in first and second world regions.
Despite the potential for “digital therapeutics” to transform the treatment landscape in behavioral health, the path through the digital development process is complex and evolving.
Objective, continuous measurements, acquired over extended periods in ethological environments, could transform the therapeutic pipeline and deepen our understanding of functionally-relevant circuit neuroscience.
Human communication is at the core of all clinical interactions, especially in mental health, since changes in social function and use of language are often among the ﬁrst noticeable clues of an emerging psychiatric illness or impending episode.
This panel discusses the hypothesis that, at least in some instances, the diagnosis and treatment of a patient with a mental illness might be aided if the treating mental health professional has access to what the patient is communicating to others via social media, emails, and texts.
Understanding the brain and human behavior with sufficient precision to accurately forecast future properties of a neural circuit or of an individual undergoing treatment for a mental health condition would transform our ability to tailor illness monitoring, circuit-based interventions, and care delivery based on those predictions.
The 2018 summit included a poster session. Over 35 abstracts were on display, with topics ranging from digital health applications to investigations of human-computer interaction, pervasive sensing, phenotyping at scale, and more.
The 2017 Technology in Psychiatry Summit was a first of its kind event targeted at bringing together the nation’s top technology and mental health experts to build on the promise of technology in the diagnosis and delivery of mental health care. Among the who’s who of presenters were Tom Insel, MD, former NIMH director, Ken Duckworth, MD, of Blue Cross Blue Shield of Massachusetts, Roz Picard, ScD, of the Affective Computing Research Group at MIT, and Sarah Lenz Lock, JD, of the AARP.
Scott L. Rauch, MD, President, McLean Hospital
Dr. Rauch is president, psychiatrist in chief, and Rose-Marie and Eijk van Otterloo Chair of Psychiatry at McLean Hospital. He is also professor of psychiatry at Harvard Medical School as well as chair of Psychiatry and Mental Health for Partners Healthcare. His principal research interests relate to neuroimaging and the neurobiology of affective disorders. Dr. Rauch and colleagues have been leaders in delineating the neurocircuitry of anxiety disorders as well as pioneers in using modern technology, including brain stimulation, neurosurgery, and internet-based methods, to develop novel treatments for anxiety and mood disorders.
Sarah H. Lisanby, MD, Division of Translational Research, National Institute of Mental Health
Dr. Lisanby is the director of the Division of Translational Research and director of the Noninvasive Neuromodulation Unit at NIMH. Her division supports research to accelerate the translation of scientific discoveries into preventions, treatments, and cures for mental illness, and her individual research focuses on neurostimulation devices and mental illness treatments.
Roz Picard, ScD, MIT Media Lab
Dr. Picard is the founder and director of the Affective Computing Research Group at the MIT Media Lab, co-director of the Media Lab’s Advancing Wellbeing Initiative, faculty chair of MIT’s MindHandHeart Initiative, and co-founder of Empatica, Inc. (creating wearable sensors and analytics for health improvement) and Affectiva Inc. (technology that measures and communicates emotion). Her inventions apply to a variety of neuropsychiatric disorders and human-computer interaction.
Thomas Insel, MD, Mindstrong Health
Dr. Insel is a neuroscientist and psychiatrist, and is the current president and co-founder of Mindstrong Health. He was formerly the director of the NIMH from 2002-2015, and more recently led the mental health division of Verily Life Sciences from 2015-2017.
Kerry J. Ressler, MD, PhD, Chief Scientific Officer, McLean Hospital
Dr. Ressler is chief scientific officer and James and Patricia Poitras Chair in Psychiatry at McLean Hospital, after serving at Emory University for 18 years. He is also a professor in psychiatry at Harvard Medical School and current president of the Society for Biological Psychiatry. Dr. Ressler’s lab focuses on translational research bridging molecular neurobiology in animal models with human genetic research on emotion, particularly fear and anxiety disorders.
Advances in technology are creating almost limitless potential sources of data for understanding health and human behavior. This panel will focus on how we can take advantage of some of these data sources in the clinic and in the research laboratory using modern data analytic and machine learning approaches to generate insights and improve clinical care.
Innovators in academia, medicine, and technology deliver brief talks on cutting-edge topics.
Recent advances in computing now allow us to measure aspects of behavior and physiology that would not have been feasible even a handful of years ago. This panel will showcase examples of cutting-edge tools for understanding the brain and behavior that are low cost and scalable, towards a future of “digital diagnostics” that can be leveraged to increase the accessibility and impact of mental health services.
Technological and social advancements are changing the way science is conducted. Methods for remote data collection, collaboration, and data sharing have led to new approaches to mental health research that transcend geographical and institutional boundaries. This panel will discuss how we might conceptualize a laboratory of the future to lead us to a better understanding of mental health, the brain, and behavior.
The implications of a rapidly growing population of older adults on health care costs, housing, and public policy are well-recognized. The world of aging is at the forefront of innovation in the use of technologies to support independent living, maximized functioning, and improvements in cost, efficiency, and personalization of clinical care. This session will focus on exploring how the worlds of aging, technology and mental health can intersect and what might be the most fruitful areas to explore within this domain.
Digital technologies have the potential to transform mental health care, particularly among groups that have traditionally been hard to reach due to lack of access, education, or resources. In this session, leading experts in technology, policy, and public health will discuss how we might take the insights generated from clinical and basic research and translate them to improvements in care and access to care. Discussion will focus on how to address the gap between the availability of mental health services and the pressing need for such services globally.
Large-scale adoption of effective digital health technologies will depend on coming up with appropriate social and technical infrastructure. At the core of this infrastructure is the need to balance privacy and security with transparency, openness, sharing, and the rights of individuals to own and make decisions about their own health and health data. In this session, leaders in privacy, access, and ethics will discuss the biggest challenges and potential ways forward in building a future where effective technologies work for society and individuals.
Approximately 1 in 5 adults in the US—43.8 million, or 18.5%—experiences mental illness in a given year. (NAMI)
High income nations, on average, spend 5% of total health spending on mental health; for lower middle-income countries the figure is less than 2%. (WHO report)
Mental health workers account for only 1% of the global health workforce and 45% of the world’s population lives in a country with less than one psychiatrist per 100,000 people. (APA report)
Nearly nine-in-ten Americans today are online, up from about half in the early 2000s. (Pew Research Center)
Roughly 3/4 of Americans (77%) now own a smartphone. (Pew Research Center)
Today just over one-in-ten American adults are “smartphone-only” internet users—meaning they own a smartphone, but do not have traditional home broadband service. (Pew Research Center)
13% of Americans don’t use the internet. (Pew September 2016)
90% of the individuals in this survey (NAMI survey, plus academic source) owned more than one digital device such as a personal computer, tablet, or smartphone. 54% had access to smartphones compared to 64% of all Americans. Many survey respondents use their devices to cope with mental illness:
Most (72%-97%) patients with mental illness have reported the use of mobile phones for activities other than spoken conversations such as sending emails, web browsing, and social networking. (National Medical Journal of India)
Individuals with severe mental illness: “93% owned cellphones, 78% used text messaging, 50% owned smartphones, and 71% used social media such as Facebook.” (Psychiatric Rehabilitation Journal)
“The average 18-25 year-old checks their phone 56 times/day.” (Bridianne O’Dea, TEDxYouth@Sydney) The phone is a direct portal.
“The global telehealth market is expected to be worth US$ 34.27 billion by the end of 2020, with North America being the largest market globally accounting for more than 40% of the global market size.” (HITconsultant)
“Three in five Americans are open to virtual support service options (e.g., video conference calls) with pharmaceutical companies to help them understand medications. This is especially true with millennials, as 70% want to leverage these modern technologies to communicate with their drug providers.” (Salesforce 2017 Connected Patient Report)
“Nearly three in four Americans (72%) say it’s important that their health insurance providers use modern tools—such as live chat/instant message and two-way video—when communicating with them.” (Salesforce 2017 Connected Patient Report)
“A majority of Americans currently communicate with their doctors via traditional channels to schedule appointments, with 80% using the phone.” (Salesforce 2017 Connected Patient Report)
Insurance companies: “Millennials are more than three times as likely than baby boomers (26% vs. 7%) to use their insurance companies to find health care providers.” (Salesforce 2017 Connected Pt Report)
Serious mental illness costs America $193.2 billion in lost earnings per year. (NAMI)
Mood disorders, including major depression, dysthymic disorder and bipolar disorder, are the third most common cause of hospitalization in the US for both youth and adults aged 18-44. (NAMI)
Smartphone ownership: “There are no differences in smartphone ownership among different racial and ethnic groups.” (Pew Research Center)
If there’s parity in tools, that means we can have parity in methods and quality of care delivered digitally.